NCT Number: NCT02211157
Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects
Study to assess safety, pharmacokinetics and pharmacodynamics of BIRB 796 BS in escalating multiple doses with and without a 64 g fat breakfast at the 50 mg dose level
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy male subjects as determined by results of screening
- Signed written informed consent in accordance with Good Clinical Practice and local legislation
- Age ≥ 18 and ≤ 45 years
- Broca ≥ - 20% and ≤ + 20%
Exclusion criteria
- Any findings of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
- Surgery of gastrointestinal tract (except appendectomy)
- History of orthostatic hypotension, fainting spells and blackouts
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (>24 hours) within 1 month prior to administration or during the trial)
- Use of any drugs which might influence the results of the trial within 10 days prior to administration or during trial
- Participation in another trial with an investigational drug within 2 months prior to administration or during trial
- Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
- Inability to refrain from smoking on study days
- Alcohol abuse (> 60 g/day)
- Drug abuse
- Blood donation > 400 ml within 1 month prior to administration or during the trial
- Excessive physical activities within 5 days prior to administration or during the trial
- Any laboratory value outside the reference range of clinical relevance including, but not limited to total white cell count ≥ 10 x 10**9/L, C-reactive protein ≥ 4.5 mg/L, Gamma-Glutamyl Transferase ≥ 40 U/L, any hemoglobin or > 15 mg/dl protein or urine dipstick, abnormal Multitest® assessment of cellular immunity
- History of any familial bleeding disorder
- Inability to comply with dietary regimen of study centre
Treatment and study plan
Placebo
DrugHigh fat breakfast
OtherPrimary outcomes
-
Number of patients with clinically relevant changes in laboratory parameters
Time frame: up to day 16
-
Number of patients with abnormal findings in electrocardiogram (ECG)
Time frame: up to day 16
-
Number of patients with adverse events
Time frame: up to 30 days
-
Assessment of tolerability on a 4-point scale
Time frame: day 16
-
Number of patients with clinically relevant changes in vital signs
Time frame: up to 16 days
Secondary outcomes
-
Maximum plasma concentration (Cmax) for several time points
Time frame: up to day 9
-
Area under the plasma concentration-time curve (AUC) for several time points
Time frame: up to day 9
-
Time to maximum concentration (tmax)
Time frame: up to day 9
-
Elimination rate constant (λz)
Time frame: up to day 9
-
Terminal half-life (t1/2)
Time frame: up to day 9
-
Mean residence time (MRT)
Time frame: up to day 9
-
Apparent clearance (CL/f)
Time frame: up to day 9
-
Apparent volume of distribution (Vz/F)
Time frame: up to day 9
-
Assessment of neutrophil and monocyte activation by ex vivo stimulation of whole blood with formyl-methionyl-leucyl-phenylalanine (fMLP)
Time frame: up to day 9
Change in the Mac-1 / L-selectin ratio
-
Assessment of neutrophil and monocyte activation by ex vivo stimulation of whole blood with tumour necrosis factor (TNF) α
Time frame: up to day 9
Change in the Mac-1 / L-selectin ratio
-
Assessment of TNFα production by ex vivo stimulation of whole blood with endotoxin
Time frame: up to day 9
-
Changes in cellular immune response measured by Multitest®
Time frame: Day 8
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets (20, 30, 150, 300, and 600 mg) Administered Orally to Healthy Human Subjects Once Daily for 7 Days. A Placebo Controlled, Randomised, Double Blinded Study
Important dates
- Study start
- 2000
- Primary completion
- 2000
- First posted
- Aug 7, 2014
- Registry last updated
- Aug 8, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Characterization of Gastric Evoked Potentials
NCT05924009
Healthy
Pittsburgh, Pennsylvania, United States
View Trial DetailsTo Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers
NCT07374406
Healthy
Jeonju, South Korea
View Trial DetailsDimensional Changes of the Keratinized Mucosa in Edentulous Ridges Following Accordian Technique Versus Conventional Free Gingival Grafts
NCT07365865
Deficient Keratinized Mucosa, Healthy
Cairo, Egypt
View Trial DetailsValidation of a Digital Twin Performing Strength Training
NCT04849923
Healthy
Winterthur, Canton of Zurich, Switzerland
View Trial Details